MIMichio Inoue

Michio Inoue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michio Inoue has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A

    by Munenori Oyama, Yuko Ohnuki, Akinori Uruha, Yoshihiko Saito, Yukako Nishimori, Shingo Suzuki, Michio Inoue, Jantima Tanboon, Naoko Okiyama, Takashi Shiina, et al.

    Objective: The diagnosis in the studies analyzing HLA of dermatomyositis (DM) was based on a combined clinical category of polymyositis/DM. This retrospective study investigated the associations of HLA with 5 DM-specific autoantibodies in Japanese patients diagnosed by muscle pathology.Methods: We diagnosed Japanese patients with DM based on sarcoplasmic expression of myxovirus resistance protein A. These patients underwent investigation for 5 DM-specific autoantibodies and HLA genotyping.Results: Of 175 patients (83 males and 92 females; range 1-86 yrs; mean 46 yrs), 173 (98.9%) had 1 of the 5 autoantibodies. Seven alleles—A*02:07, B*46:01, DRB1*04:07, DRB1*07:01, DRB1*08:03, DQB1*06:01, andDPB1*02:02—were more frequently detected in the patients with DM than healthy controls, but these associations were not significant after multiple testing correction. Stratifying by DM-specific autoantibodies, we found the associations of 6 already known and 7 new alleles—B*48:01, B*52:01, C*12:02, DRB1*04:05, DRB1*15:02, DPB1*05:01, andDPB1*09:01—with subsets of DM. Moreover, significant associations of 5 alleles with antinucleosome remodeling deacetylase complex (Mi-2) remained after multiple testing correction. In particular, theDRB1*04:07(odds ratio [OR 28.9]; correctedP= 2.7 × 10−6) andDQB1*06:01(OR 4.0; correctedP= 1.6 × 10−4) alleles were significantly more prevalent in patients with anti-Mi-2 antibody than in controls.Conclusion: This study demonstrates DM-specific autoantibodies defined immunogenetic subsets of DM.


  • Open Access

    A deep convolutional neural network-based algorithm for muscle biopsy diagnosis outperforms human specialists

    by Yoshinori Kabeya, Mariko Okubo, Sho Yonezawa, Hiroki Nakano, Michio Inoue, Masashi Ogasawara, Yoshihiko Saito, Jantima Tanboon, Luh Ari Indrawati, Theerawat Kumutpongpanich, et al.

    Histopathologic evaluation is essential for categorizing and studying neuromuscular disorders. However, experienced specialists and pathologists are limited, especially in underserved areas. Although new technologies, such as artificial intelligence, are expected to improve medical reach, their use in rare diseases is challenging because of the limited availability of training datasets. To address this knowledge gap, we developed an algorithm based on deep convolutional neural networks that used data from microscopic images of hematoxylin-and-eosin-stained pathology slides. Our algorithm differentiated idiopathic inflammatory myopathies (mostly treatable) from hereditary muscle diseases (mostly non-treatable) and achieved better sensitivity and specificity than real physicians' diagnoses. Furthermore, it successfully and accurately classified four subtypes of the abovementioned muscular conditions. These results suggest that our algorithm can be safely used in a clinical setting. We established the similarity between the algorithm's and physicians' predictions using visualization technology, and clarified the validity of the predictions.